Sign In
HomeNewsKolling unveils new research strategy

Kolling unveils new research strategy

The Kolling Institute Research Strategy launched at the end of February, setting the strategic framework for the next five years and broadening opportunities to achieve high-quality translational research.

Three research priority areas have been identified during the formation of the strategy including musculoskeletal, neuroscience and pain, and cardiovascular and renal research.

Kolling Institute Executive Director Professor Carolyn Sue said these areas of research investigate some of the biggest health challenges of our time.

“Collectively, they cost the community billions of dollars a year in health, personal and economic costs,” she said.

There is tremendous expertise across these disciplines within the Kolling, with many researchers world renowned in their fields. Our research teams have a track record of success, a unique breadth of skills and knowledge and globally recognised expertise.
Kolling Institute Executive Director Professor Carolyn Sue


“By focusing on these areas, we are moving to strengthen our ability to achieve game-changing research and ultimately improve the health of our community.”

A key component of the new strategy is the provision of research enablers, which will be instrumental in providing collaborative opportunities, modern platforms and infrastructure, and diversified funding.

The research enablers will focus on the following areas:

  • Clinical trials and translation
  • Data and informatics
  • Research infrastructure and support services
  • Recruitment and retention

Carolyn said the strategy will identify opportunities for the Kolling to become a national leader in clinical trials and translational practice, building on existing strengths in this area.

“Our researchers work within Royal North Shore Hospital, one of Sydney’s largest tertiary hospitals, with extensive access to patient groups and state of the art facilities,” she said.

“This means our teams can directly incorporate scientific discoveries and evidenced-based improvements into patient care.

“We expect there will be a greater involvement in industry trials by building on our expertise and reputation as a leader in clinical trials.

“The measures incorporated in the new strategy are aimed at assisting teams to increase the impact of their research.

“They will provide a robust strategic framework, delivering new opportunities, greater assistance, access to high quality facilities and new partnerships both within and outside the organisation.”

What others found interesting…